Ellison says the agreement requires Denmark-based manufacturer Novo Nordisk to cap monthly out-of-pocket payments for insulin at $35 a month for the next five years, even for people without health ...

Novo Nordisk (NVO) has reportedly settled a lawsuit filed by the state of Minnesota over the pricing of its insulin products by agreeing to cap costs at $35 per month. Under the settlement, Novo ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Jan 27 (Reuters) - Novo Nordisk , opens new tab agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging ...

Novo Nordisk NOVO.B0.48%increase; green up pointing triangle shares rallied Wednesday as investors breathed a sigh of relief after first-quarter earnings beat expectations and the company’s ...

Novo Nordisk will invest around $1 billion to expand its production site in Montes Claros, Brazil, marking one of the largest pharmaceutical investments in the nation’s history.The company’s ...

Novo’s weight-loss drugs are administered by injection and a pill version would be more convenient for patients, ... Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills.

Novo Nordisk (NVO 1.20%) has enjoyed tremendous success with semaglutide, the proprietary drug in Ozempic and Wegovy. However, competition is picking up with multiple next-generation drugs working ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market has grown fiercer. By Rebecca Robbins Novo Nordisk will replace its ...